Biosoft aims to become a conductor between fundamental science and services. It helps business representatives to find appropriate scientific partners.
VISION AND MISSION
Biosoft aims to put on stream fundamental science problems that phramaceutical and other lifesciences companies are forced to deal with in order to get a desired result.
The BioUML platform is certified and intellectual rights on it totally belong to the Biosoft company
Biosoft is totally responsible for the quality of all of the services it provides.
Our top management team unites experts in science and administration, that's why Biosoft is developing quickly and efficiently.
Biosoft has collected a team of real experts to grant you top quality scientific services.
The Genome Enhancer prospective drug target identification pipeline was highly evaluated by the attendees of the past TRI-CON 2020 exhibition in San Francisco. We have received lots of positive feedback regarding our tool and the perspective of its application in the biomedical research field.
According to an independent comparison, our platform was recognized as the most accurate and fast SBML simulator based on a set of 613 curated models from BioModels database.
We have received lots of extremely valuable feedback on improving our system for the needs of medical doctors while showing Genome Enhancer to real oncologists at this huge congress. It was truly great to receive all these comments full of excitement from the world’s most advanced doctors!
The Biosoft company was found in 2008 by Alexander Kel and Fedor Kolpakov with guidance of Institute of Systems Biology, Novosibirsk. The founders of Biosoft at that time had one main idea they wanted to bring to life: they wanted to put on stream the solution of a fundamental scientific problem all pharmaceutical companies had to deal with: the verification and validation of a therapeutic target and compound. This aim brought Alexander and Fedor to understanding of necessity in development of a unified information platform for biomedical data analysis. Fedor has already been working on a prototype of such platform from 2003, so in a relatively short time a commercial version of BIO UML platform was ready. The BioUML platform can be easily updated by uploading new modules to it. In 2009 Alexander Kel and Fedor Kolpakov have worked out an idea of outsourcing new modules for BioUML platform from third-party developers. This could make this platform a real leader in the biomedical data analysis software market as the number of applications now could be increased greatly via the crowdsourcing strategy, Biosoft has started a project of developing such a platform and thanks to the Skolkovo Foundation, which invested 5 mln. rubles by a minigrant in 2012 to this project, the BioUML platform is now being prepared for crowdsourcing.
In 2012 a new idea came to the founders of Biosoft. They decided not only to make an information platform for biomedical data analysis, they had an idea of opening a real science services online exchange market. Any scientific organization (CRO or an academic institute - it doesn't matter) could register on the Biosoft web site and hang out their services list. The services and companies could then be set up in a certain order by the staff of Biosoft project and later on a client could find any scientific service he needs. Moreover, Biosoft could provide an unprecedented approach of handling a turnkey approach to drug development by simply gathering all the drug discovery stages into one continuous process. Biosoft is currently looking for investments to bring this great idea to life.